ESC 365 - SGLT2i on transthyretin amyloid cardiomyopathy - a new drug for an under-recognized cardiomyopathy

Back

HFA Premium Access

SGLT2i on transthyretin amyloid cardiomyopathy - a new drug for an under-recognized cardiomyopathy

Session: ePosters in chronic heart failure - pharmacotherapy 5

Topic: Pharmacotherapy

Speaker: Mr D. Inacio Cazeiro (Lisbon, PT)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Mr Daniel Filipe Inacio Cazeiro

Hospital Santa Maria, Lisbon (Portugal)

1 presentation

0 follower

7 more presentations in this session

Clinical practice associated with 6-month use of patiromer in patients with heart failure

Speaker: Doctor I. ARAUJO (Lisbon, PT)

Remote monitoring in a virtual ward safely facilitates the rapid up-titration of prognostic medication for heart failure with reduced ejection fraction patients

Speaker: Doctor A. Kirupananthavel (London, GB)

Single centre 3-year experience in intermittent levosimendan infusion

Speaker: Doctor F. Gerardo (Amadora, PT)

Initial experience of vericiguat treatment in patients with heart failure and high risk of decompensation.

Speaker: Doctor M. Groba Marco (Las Palmas de Gran Canaria, ES)

SGLT2 inhibitors impact on loop diuretic requirement in a community heart failure cohort

Speaker: Doctor M. Killian (Dublin, IE)

Access the full session

ePosters in chronic heart failure - pharmacotherapy 5

Speakers: Mr D. Inacio Cazeiro, Doctor I. ARAUJO, Doctor A. Kirupananthavel, Doctor F. Gerardo, Doctor M. Groba Marco...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources